Tempus AI, Inc (TEM)

48.82 +2.84 (+6.18%) At close: 04:00PM EDT

Tempus AI, Inc

600 West Chicago Avenue
Suite 510
Chicago, IL 60654
United States
(800) 976-5448
https://www.tempus.com

Sector(s): Healthcare
Industry: Health Information Services
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Eric P. Lefkofsky	Co-Founder, CEO, President & Chairman	2.1k	N/A	1970
Mr. James Rogers	Chief Financial Officer	543.77k	N/A	1986
Mr. Ryan Fukushima	Chief Operating Officer	N/A	N/A	1985
Mr. Ryan M. Bartolucci	Chief Accounting Officer	N/A	N/A	1982
Mr. Shane Colley	Chief Technology Officer	N/A	N/A	N/A
Dr. Kate A. Sasser Ph.D.	Chief Scientific Officer	N/A	N/A	1977
Mr. Erik Phelps	Executive VP, Assistant Secretary and Chief Administrative & Legal Officer	N/A	N/A	1971
Ms. Patty Spiller	Senior Vice President of Marketing	N/A	N/A	N/A
Ms. Christina Antoniou	Senior VP & Head of Corporate Development	N/A	N/A	N/A
Ms. Stacey Kraft	Chief People Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a collaboration with united therapeutics to study use of AI to detect patients at risk for pulmonary hypertension. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc in January 2023. Tempus AI, Inc was incorporated in 2015 and is headquartered in Chicago, Illinois.

Corporate governance

Tempus AI, Inc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.